Why HIV Virions Have Low Numbers of Envelope Spikes: Implications for Vaccine Development

article has not abstract

Vyšlo v časopise: Why HIV Virions Have Low Numbers of Envelope Spikes: Implications for Vaccine Development. PLoS Pathog 10(8): e32767. doi:10.1371/journal.ppat.1004254
Kategorie: Pearls
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004254

Souhrn

article has not abstract

Zdroje

1. ZhuP, LiuJ, BessJJr, ChertovaE, LifsonJD, et al. (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441: 847–852.

2. PowersKA, PooleC, PettiforAE, CohenMS (2008) Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 8: 553–563.

3. YusteE, ReevesJD, DomsRW, DesrosiersRC (2004) Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol 78: 6775–6785.

4. KleinJS, BjorkmanPJ (2010) Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 6: e1000908.

5. HangartnerL, ZinkernagelRM, HengartnerH (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6: 231–243.

6. StanleyM (2010) HPV - immune response to infection and vaccination. Infect Agent Cancer 5: 19.

7. SchillerJT, LowyDR (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 10: 681–692.

8. SafaeianM, PorrasC, PanY, KreimerA, SchillerJT, et al. (2013) Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 6: 1242–1250.

9. BachmannMF, ZinkernagelRM (1996) The influence of virus structure on antibody responses and virus serotype formation. Immun Today 17: 553–558.

10. ChackerianB, LowyDR, SchillerJT (2001) Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108: 415–423.

11. ChackerianB, LenzP, LowyDR, SchillerJT (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169: 6120–6126.

12. ChackerianB, DurfeeMR, SchillerJT (2008) Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 180: 5816–5825.

13. BachmannMF, WhiteheadP (2013) Active immunotherapy for chronic diseases. Vaccine 31: 1777–1784.

14. WardemannH, YurasovS, SchaeferA, YoungJW, MeffreE, et al. (2003) Predominant autoantibody production by early human B cell precursors. Science 301: 1374–1377.

15. YarkoniY, GetahunA, CambierJC (2010) Molecular underpinning of B-cell anergy. Immunol Rev 237: 249–263.

16. MascolaJR, HaynesBF (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254: 225–244.

17. WestAPJr, ScharfL, ScheidJF, KleinF, BjorkmanPJ, et al. (2014) Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156: 633–648.

18. YangG, HollTM, LiuY, LiY, LuX, et al. (2013) Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 210: 241–256.

19. VerkoczyL, DiazM (2014) Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS 9: 224–234.

20. WistromJ, AhlmC, LundbergS, SettergrenB, TarnvikA (1999) Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 17: 2162–2165.